CN116531377A - 一种pH响应模拟缺氧效应纳米微球的制备方法及应用 - Google Patents
一种pH响应模拟缺氧效应纳米微球的制备方法及应用 Download PDFInfo
- Publication number
- CN116531377A CN116531377A CN202310507069.2A CN202310507069A CN116531377A CN 116531377 A CN116531377 A CN 116531377A CN 202310507069 A CN202310507069 A CN 202310507069A CN 116531377 A CN116531377 A CN 116531377A
- Authority
- CN
- China
- Prior art keywords
- solution
- hypoxia
- nano
- deionized water
- microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 65
- 230000007954 hypoxia Effects 0.000 title claims abstract description 58
- 230000000694 effects Effects 0.000 title claims abstract description 47
- 230000004044 response Effects 0.000 title claims abstract description 25
- 239000004005 microsphere Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000002105 nanoparticle Substances 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 24
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 19
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 239000008367 deionised water Substances 0.000 claims abstract description 16
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011258 core-shell material Substances 0.000 claims abstract description 8
- 239000000047 product Substances 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004471 Glycine Substances 0.000 claims abstract description 4
- 239000008098 formaldehyde solution Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 abstract description 24
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 14
- 238000004088 simulation Methods 0.000 abstract description 9
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000008092 positive effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 210000002540 macrophage Anatomy 0.000 description 17
- 230000002757 inflammatory effect Effects 0.000 description 16
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 14
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 9
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 9
- 230000010287 polarization Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 6
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 6
- 239000002077 nanosphere Substances 0.000 description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000003239 periodontal effect Effects 0.000 description 4
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002539 nanocarrier Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 2
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 2
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 2
- 102000002177 Hypoxia-inducible factor-1 alpha Human genes 0.000 description 2
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 2
- 238000006683 Mannich reaction Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108010031256 phosducin Proteins 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- -1 Dimethoxypropylglycine Chemical compound 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710114687 Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000006108 VHL Human genes 0.000 description 1
- 101150046474 Vhl gene Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002590 marrow fibroblast Anatomy 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000011807 nanoball Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 101150005399 sod2 gene Proteins 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明适用于生物医药材料技术领域,提供了一种pH响应模拟缺氧效应纳米微球的制备方法,包括以下步骤:将20mg的EGCG溶于2ml去离子水中,加入5mg甘氨酸和10μl甲醛溶液并搅拌,获得乳白色溶液并离心处理,弃上清并洗涤离心产物两次,得到直径为200nm的球形纳米粒子;测量球形纳米粒子含量并将浓度调为20mg/ml。将球形纳米粒子和缺氧模拟药FG‑4592以1.5/1的比例反应得到直径为60nm的核壳形状微球,这种载药纳米微球,不仅可以在牙周炎环境中响应释放精准用药,避免各种不良反应,提高纳米药物的治疗效率,其本身的抗氧化抗炎作用也对治疗牙周炎有积极的作用,在临床治疗中具有广阔的应用前景。
Description
技术领域
本发明属于生物医药材料技术领域,尤其涉及一种pH响应模拟缺氧效应纳米微球的制备方法及应用。
背景技术
牙周炎是一种高发口腔疾病,世界卫生组织统计结果显示,全球约有10%-15%的人口患有严重的牙周疾病,使患者的生活质量和全身健康都受到了极大的影响。目前认为牙周炎的发病机制是牙菌斑生物膜作为始动因子侵袭牙周组织后,机体会产生大量的炎症因子进行防御,有效地执行宿主防御反应。牙周炎是机体固有免疫和适应性免疫调节的结果,如未获得及时的治疗最终会导致结缔组织附着和牙槽骨等牙齿支持结构丧失,最终牙齿脱落影响人的生活质量。目前最常用的治疗方法包括龈上洁治和根面刮治等机械方法,并不能有效去除窄而深牙周袋中的菌斑。并且菌斑生物膜只是牙周炎的始动因子,控制细菌感染诱发的机体免疫防御反应,进而控制炎症,并促进牙周组织再生仍然是临床医生面临的问题。考虑到宿主免疫反应在牙周炎组织破坏中的突出作用,其中巨噬细胞向M1表型(促炎症)的极化与牙周炎症的破坏密切相关,而M2型巨噬细胞在炎症消退、组织修复中发挥作用,因此调节巨噬细胞极化可能是治疗牙周炎的靶点。
缺氧是炎症部位的常见特征。在正常发育和分化中以及在病理环境中,如癌症和缺血,细胞适应缺氧条件的能力是至关重要的。缺氧诱导因子(Hypoxia-induciblefactors,HIFs)的转录因子家族在很大程度上协调细胞对缺氧的应答,调控不同的靶基因表达来调节糖酵解、血管生成、能量代谢以及细胞增殖和生存。缺氧诱导因子1(HIF-1)在氧调控基因的表达中起核心作用,由α-亚基(HIF-1α)和β-亚基(HIF-1β)组成。HIF-1β在细胞中稳定表达,而HIF-1α在正常氧生物利用度条件下被脯氨酸羟化酶(prolylhydroxylases,PHDs)羟基化两个脯氨酸残基,接着被包含von Hippel-Lindau蛋白(pVHL)的蛋白质复合物识别,最终降解。在缺氧环境中可以迅速积累。大量研究表明HIFs是先天免疫和适应性免疫的关键调节因子,通过调节代谢等调控巨噬细胞极化调节炎症反应。因此,模拟缺氧效应,靶向HIFs通路可能是治疗炎症的一个关键的问题和重要的策略。本研究中我们使用一种PHD抑制剂FG-4592(Roxadustat)来模拟缺氧效应上调HIF-1α的表达来调控巨噬细胞极化调节炎症。FG-4592经FDA批准是一种用于临床治疗肾性贫血的口服药。口服用药会引起全身副作用,而直接局部用药会被口腔环境的溶解,达不到有效的药物浓度。因此,应用一种可以局部递送至牙周部位且能够在牙周炎碱性环境下响应释放的纳米载体是关键的。
与其他大多数炎症酸性环境不同的是,牙周炎是一个碱性微环境,其龈沟液pH明显呈弱碱性反应,有研究表明PH值约在8.10±0.57。这可能是因为牙周袋加深造成厌氧环境使局部氧化还原电势降低使PH升高,另外大部分厌氧菌能产生组织胺等碱性还原物质,也会使局部pH值升高。然而目前大多数载体都是在酸性环境下释放药物。因此,选用一种能够在碱性环境下释放药物的纳米载体是一个关键问题。局部组织缺氧是感染和炎症的一个特征,HIF-1调控不同的靶基因来调节糖酵解、血管生成、能量代谢以及细胞增殖和生存,在氧调控基因的表达中起核心作用。HIFs是由α-亚基(HIF-αs)和β-亚基(HIF-1β)组成的一种转录激活因子复合体。HIF-1β在细胞中稳定表达,而HIF-αs在正常氧生物利用度条件下(>5%),被脯氨酸羟化酶(prolyl hydroxylases,PHDs)结合并羟化脯氨酸残基,随后被多聚泛素化降解。在缺氧条件下,PHD活性被抑制,HIF-1α能稳定表达。据报道,HIF-1α可以调节巨噬细胞极化,降低M1/M2型细胞的比例,抑制炎症反应。因此,模拟缺氧效应,上调HIF-1α的表达是解决炎症的重要科学问题。增加HIF表达的药物被称为缺氧模拟剂。先前的研究报告的低氧模拟剂,包括二价铁离子拮抗剂如CoCl2和DFX,脯氨酸羟化酶的竞争性抑制剂如二甲氧丙烯甘氨酸(DMOG),然而他们都有毒性较高、脱靶副作用等缺点。FG-4592是一种新型脯氨酰羟化酶抑制剂,采用基于结构的药物设计(SBDD)和高通量筛选(HTS)技术开发,已经通过FDA批准用于治疗的慢性肾性贫血。与传统的缺氧模拟剂相比,FG-4592具有更高的靶向特异性和更安全的临床应用。近年来,有研究表明,FG-4592稳定HIF-1α表达,增加对缺氧的耐受性,从而改善如肾性贫血、脊髓损伤、视网膜疾病,皮肤伤口的愈合,骨折愈合等许多疾病的预后。同时,FG-4592也被证明可以通过增加HIF-1α靶基因超氧化物歧化酶2(SOD2)、核因子红系2相关因子2(Nrf-2)和介导ROS解毒的血红素加氧酶-1(HO-1)的表达来平衡氧化应激。HIFs在先天免疫细胞中表现出特定的激活和独特的表达模式,因此,我们应用FG-4592来稳定HIF-1α的表达,来调控巨噬细胞极化,调节免疫反应,治疗炎症。
发明内容
本发明实施例的目的在于提供一种pH响应模拟缺氧效应纳米微球的制备方法及应用,旨在解决FG-4592口服用药会引起全身副作用,而直接局部用药会被口腔环境的溶解,达不到有效的药物浓度的问题。
本发明是这样实现的,一种pH响应模拟缺氧效应纳米微球的制备方法及应用,包括以下步骤:
步骤一、将20mg的EGCG溶于2ml去离子水中得到溶液A;
步骤二、向溶液A内加入5mg甘氨酸和10μl甲醛溶液并搅拌,获得乳白色溶液;
步骤三、对乳白色溶液离心处理,弃上清并用去离子水洗涤离心产物两次,得到直径为200nm的球形纳米粒子;
步骤四、测量球形纳米粒子含量,并将球形纳米粒子浓度调为20mg/ml;
步骤五、取100μl的浓度为20mg/ml的球形纳米粒子溶液,并加入20%的无水乙醇,乳白色溶液变为澄清溶液;
步骤六、称量1.3mg的FG-4592将其溶解在10μl的二甲基亚砜中得溶液B;
步骤七、将溶液B加入澄清溶液中,随后分两次共加入1600μl的去离子水,每次800μl;
步骤八、在摇床上反应10分钟后,离心处理5分钟,弃上清并用去离子水洗涤离心产物2次,得到直径为60nm的载药核壳形状的微球。
进一步的技术方案,步骤二中搅拌在室温下进行,且以550转/分钟的速率搅拌20分钟。
进一步的技术方案,步骤三中离心处理具体以8500转/分钟的转速离心10分钟。
进一步的技术方案,所述步骤八中摇床转速为250转/分钟,所述步骤八中离心处理的转速为12000转/分钟。
一种pH响应模拟缺氧效应纳米微球在炎症疾病中的应用,所述pH响应模拟缺氧效应纳米微球由上述的pH响应模拟缺氧效应纳米微球的制备方法制备而得。
本发明实施例提供的一种pH响应模拟缺氧效应纳米微球的制备方法及应用,多酚类药物表没食子儿茶素没食子酸酯(Epigallocatechin gallate,EGCG)也具有较强地抗氧化和抗炎作用,我们以EGCG、醛和氨基酸为原料,采用曼尼希缩合(Mannich反应)法合成了EGCG低聚物(EGCG CSs),并将药物FG-4592加载其中,形成一种核壳状的纳米微球。这种纳米微球在牙周炎症的微碱环境中响应释放,模拟缺氧效应上调HIF-1α,调节巨噬细胞M1和M2型极化,调节固有免疫,抑制炎症反应,这为牙周炎的治疗提供了一种有前景的方法。我们选用的EGCG低聚物可以在碱性环境下拆解而释放药物,这样防止药物单独应用时在口腔复杂的环境中不稳定而溶解。另外构建纳米药物还可以克服药物水溶性差、生物利用度低、分布不特异等缺点。因此,利用具有治疗作用的纳米载体EGCG,不仅可以在牙周炎环境中响应释放精准用药,避免各种不良反应,提高纳米药物的治疗效率,其本身的抗氧化抗炎作用也对治疗牙周炎有积极的作用,在临床治疗中具有广阔的应用前景。
附图说明
图1为本发明实施例提供的直径为200nm的球形纳米粒子GCS的透射电镜图片;
图2为本发明实施例提供的直径为60nm的载药核壳形状的微球的透射电镜图片;
图3为本发明实施例提供的pH响应模拟缺氧效应纳米微球的紫外曲线;
图4为本发明实施例提供的pH响应模拟缺氧效应纳米微球的水合粒径分布;
图5为本发明实施例提供的pH响应模拟缺氧效应纳米微球的ZETA电位;
图6为本发明实施例提供的pH响应模拟缺氧效应纳米微球的傅里叶变换红外光谱图;
图7为本发明实施例提供的pH响应模拟缺氧效应纳米微球在PBS中的释放曲线图;
图8为本发明实施例提供的pH响应模拟缺氧效应纳米微球在体外骨髓间充质干细胞和成纤维细胞的生物安全性评价图;
图9为本发明实施例提供的pH响应模拟缺氧效应纳米微球在大鼠体内的生物安全性评价图;
图10为本发明实施例提供的pH响应模拟缺氧效应纳米微球在体外细胞急性炎症期炎性基因和抗炎基因和HIF-1α基因的表达情况;
图11为本发明实施例提供的pH响应模拟缺氧效应纳米微球在体外细胞慢性炎症期炎性基因和抗炎基因和HIF-1α基因的表达情况;
图12为本发明实施例提供的pH响应模拟缺氧效应纳米微球在体外细胞慢性炎症期炎性和抗炎因子蛋白的免疫荧光图像;
图13为本发明实施例提供的pH响应模拟缺氧效应纳米微球在体外细胞慢性炎症期巨噬细胞表面标志物表达的流式细胞术结果图;
图14为本发明实施例提供的pH响应模拟缺氧效应纳米微球在体外细胞检测活性氧(ROS)清除能力的结果图;
图15为本发明实施例提供的pH响应模拟缺氧效应纳米微球在体外细胞通过蛋白免疫印迹法检测HIF-1α蛋白的表达;
图16为本发明实施例提供的pH响应模拟缺氧效应纳米微球动物实验示意图;
图17为本发明实施例提供的pH响应模拟缺氧效应纳米微球用于大鼠牙周炎模型的牙龈组织H&E染色和Masson染色图;
图18为本发明实施例提供的pH响应模拟缺氧效应纳米微球用于大鼠牙周炎模型牙龈组织的IL-1β和Arg-1的免疫组化染色图;
图19和图20分别为本发明实施例提供的pH响应模拟缺氧效应纳米微球用于大鼠牙周炎模型牙龈组织的TNF-α和IL-10免疫荧光染色图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
以下结合具体实施例对本发明的具体实现进行详细描述。
实施例一,为本发明一个实施例提供的一种pH响应模拟缺氧效应纳米微球的制备方法及应用,包括以下步骤:
步骤一、将20mg的EGCG溶于2ml去离子水中得到溶液A;
步骤二、向溶液A内加入5mg甘氨酸和10μl甲醛溶液并搅拌,获得乳白色溶液;步骤二中搅拌在室温下进行,且以550转/分钟的速率搅拌20分钟;
步骤三、对乳白色溶液离心处理,弃上清并用去离子水洗涤离心产物两次,得到直径为200nm的球形纳米粒子(GCS);步骤三中离心处理具体以8500转/分钟的转速离心10分钟;
步骤四、测量球形纳米粒子(GCS)含量,并将球形纳米粒子浓度调为20mg/ml;
步骤五、取100μl的浓度为20mg/ml的球形纳米粒子(GCS)溶液,并加入20%的无水乙醇,乳白色溶液变为澄清溶液;
步骤六、称量1.3mg的FG-4592将其溶解在10μl的二甲基亚砜中得溶液B;
步骤七、将溶液B加入澄清溶液中,随后分两次共加入1600μl的去离子水,每次800μl;所述步骤八中摇床转速为250转/分钟,所述步骤八中离心处理的转速为12000转/分钟;
步骤八、在摇床上反应10分钟后,离心处理5分钟,弃上清并用去离子水洗涤离心产物2次,得到直径为60nm的载药核壳形状的微球。
根据图3可知,载药纳米粒子GCS@FG-4592已经成功载上药物FG-4592。
根据图7可知,本发明的纳米粒子在PH=7.4的环境中2小时内释放药物达80%。
根据图8可知体外实验中FG4592药物浓度不高于20μM时对细胞有良好的生物安全性。
根据图9可知药物浓度在24mM时(GCS@FG-4592组)和48mM(GCS@FG-4592’组)时,对动物的心、肝、脾、肺、肾均有良好的生物安全性。
根据图10可知,本发明的载药纳米粒子,在急性炎症期炎性基因TNF-α、iNOS和IL-1β表达明显降低,且具有统计学意义,抗炎基因IL-10和TGF-β的表达显著增加。缺氧诱导因子1α表达也明显增加。由此可见,缺氧模拟纳米粒子对急性炎症有一定的抗炎作用,并且抑制M1型巨噬细胞相关的炎性因子,促进M2型巨噬细胞相关的抗炎因子表达。
根据图11可知,在炎性因子TNF-α、iNOS和IL-1β表达明显减少,抗炎因子IL-10,Arg-1表达显著增加,缺氧诱导因子1α表达明显增加。由此可见,本发明的缺氧模拟纳米粒子对慢性炎症有一定的抗炎作用。
根据图12可知炎性蛋白TNF-α,IL-1β缺氧模拟纳米粒子组表达都明显减少,抗炎蛋白IL-10,Arg-1缺氧模拟纳米粒子组表达增加。由此可见,从蛋白水平上证明本发明的缺氧模拟纳米粒子对慢性炎症有一定的抗炎作用。
根据图13可知,标志M1型巨噬细胞的CD86表达有减少,但是不很显著,标志M2型巨噬细胞的CD206表达明显增加,由此可见本发明的缺氧模拟纳米粒子可以显著地促进巨噬细胞向M2型巨噬细胞极化。
根据图14可知本发明的缺氧模拟纳米粒子活性氧染色明显减少,说明抗氧化能力较强。通过检测ROS的清除程度从而可以评价抗氧化能力。
根据图15可知本发明的缺氧模拟纳米粒子可以明显使HIF-1α蛋白稳定表达。
图16,选取6周的雄性Wistar大鼠,进行牙周局部注射P.gingivalis引发牙周炎,建立牙周炎动物模型。用10%水合氯醛(0.4mL/100g)麻醉的大鼠,在下颌切牙唇侧龈沟内注射100μL P.gingivalis 3天,诱导炎症反应。为了消除炎症,用生理盐水,EGCG,GCS@FG-4592(24mM),GCS@FG-4592(48mM)以0.2mL剂量注射入龈沟内,注射4天。由图可见,GCS@FG-4592组和GCS@FG-4592’组治疗组牙龈都无明显红肿。由此可见,本发明的缺氧模拟纳米粒子对牙周炎有一定的治疗效果。
根据图17可知,缺氧模拟纳米粒子GCS@FG-4592组和GCS@FG-4592’治疗组牙龈组织炎细胞明显减少,胶原纤维明显增加。由此可见,本发明的缺氧模拟纳米粒子对大鼠牙周炎有明显的治疗效果。
根据图18可知,缺氧模拟纳米粒子GCS@FG-4592组和GCS@FG-4592’治疗组牙龈组织炎性因子IL-1β蛋白表达显著减少,Arg-1蛋白表达显著增加。由此可见,本发明的缺氧模拟纳米粒子通过调节巨噬细胞极化,来治疗大鼠牙周炎并有良好的效果。
根据图18,19可知,缺氧模拟纳米粒子GCS@FG-4592组和GCS@FG-4592’治疗组牙龈组织炎性因子TNF-α蛋白表达减少,Arg-1蛋白表达显著增加。由此可见,本发明的缺氧模拟纳米粒子可以调节巨噬细胞分型调节免疫,对大鼠牙周炎有良好的效果。
本发明上述实施例中提供了一种pH响应模拟缺氧效应纳米微球,EGCG采用曼尼希缩合(Mannich反应)法合成了微球EGCG低聚物(EGCG CSs),EGCG CSs在有机溶剂中拆解,加入水后重新自组装成直径更加小的纳米微球。在重组的过程中加入FG4592药物,产物在电镜下可见呈核壳状微球,直径约为60nm。此核壳状微球具有pH响应特性,在pH约为7.4的环境中拆解,在微酸环境中也可以缓慢释放药物。释放的药物FG-4592是脯氨酰羟化酶(PHD)的强效小分子抑制剂,可以模拟缺氧环境而上调缺氧诱导因子HIF-1α,进而调控下游的信号来抑制炎症。本发明制备方法的反应条件温和,室温即可;可以通过改变加水的频率来调控纳米微球的尺寸;实验简单、重复性好,适合批量生产。本方法以EGCG为原料,EGCG作为一种抗氧化剂,在抗炎中也发挥着良好的作用。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种pH响应模拟缺氧效应纳米微球的制备方法,其特征在于,包括以下步骤:
步骤一、将20mg的EGCG溶于2ml去离子水中得到溶液A;
步骤二、向溶液A内加入5mg甘氨酸和10μl甲醛溶液并搅拌,获得乳白色溶液;
步骤三、对乳白色溶液离心处理,弃上清并用去离子水洗涤离心产物两次,得到直径为200nm的球形纳米粒子;
步骤四、测量球形纳米粒子含量,并将球形纳米粒子浓度调为20mg/ml;
步骤五、取100μl的浓度为20mg/ml的球形纳米粒子溶液,并加入20%的无水乙醇,乳白色溶液变为澄清溶液;
步骤六、称量1.3mg的FG-4592将其溶解在10μl的二甲基亚砜中得溶液B;
步骤七、将溶液B加入澄清溶液中,随后分两次共加入1600μl的去离子水,每次800μl;
步骤八、在摇床上反应10分钟后,离心处理5分钟,弃上清并用去离子水洗涤离心产物2次,得到直径为60nm的载药核壳形状的微球。
2.根据权利要求1所述的pH响应模拟缺氧效应纳米微球的制备方法,其特征在于,步骤二中搅拌在室温下进行,且以550转/分钟的速率搅拌20分钟。
3.根据权利要求1所述的pH响应模拟缺氧效应纳米微球的制备方法,其特征在于,步骤三中离心处理具体以8500转/分钟的转速离心10分钟。
4.根据权利要求1所述的pH响应模拟缺氧效应纳米微球的制备方法,其特征在于,所述步骤八中摇床转速为250转/分钟,所述步骤八中离心处理的转速为12000转/分钟。
5.一种pH响应模拟缺氧效应纳米微球在炎症疾病中的应用,所述pH响应模拟缺氧效应纳米微球由权利要求1-4中任一项所述的pH响应模拟缺氧效应纳米微球的制备方法制备而得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310507069.2A CN116531377B (zh) | 2023-05-08 | 一种pH响应模拟缺氧效应纳米微球的制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310507069.2A CN116531377B (zh) | 2023-05-08 | 一种pH响应模拟缺氧效应纳米微球的制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116531377A true CN116531377A (zh) | 2023-08-04 |
CN116531377B CN116531377B (zh) | 2024-06-21 |
Family
ID=
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111420055A (zh) * | 2020-05-07 | 2020-07-17 | 吉林大学 | 一种磁靶向自供氧纳米粒子及其制备方法和应用 |
CN114191567A (zh) * | 2021-12-13 | 2022-03-18 | 吉林大学 | 一种多功能纳米复合材料及其制备方法和应用 |
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111420055A (zh) * | 2020-05-07 | 2020-07-17 | 吉林大学 | 一种磁靶向自供氧纳米粒子及其制备方法和应用 |
CN114191567A (zh) * | 2021-12-13 | 2022-03-18 | 吉林大学 | 一种多功能纳米复合材料及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6865193B2 (ja) | 寿命を拡大させ、かつ加齢関連疾患の発症を遅らせるための方法 | |
JP3674873B2 (ja) | 非ステロイド系抗−炎症剤および事実上非抗生物性のテトラサイクリンを含む組成物 | |
US8778882B2 (en) | Agent for strengthening calcium containing tissue and use thereof | |
US20020155174A1 (en) | Acidified nitrite as an antimicrobial agent | |
Liu et al. | Bioresponsive nanotherapy for preventing dental caries by inhibiting multispecies cariogenic biofilms | |
Ozawa et al. | Redox injectable gel protects osteoblastic function against oxidative stress and suppresses alveolar bone loss in a rat peri-implantitis model | |
KR100597170B1 (ko) | 파킨슨병 치료용 릴루졸과 레보도파 배합물 | |
EP2484340B1 (en) | Collagen production accelerating composition | |
JPH03227931A (ja) | 非ステロイド抗炎症剤及びテトラサイクリンの配合 | |
Wang et al. | pH and lipase-responsive nanocarrier-mediated dual drug delivery system to treat periodontitis in diabetic rats | |
JP4700808B2 (ja) | フルボ酸、および種々の状態の処置におけるその使用 | |
Chen et al. | ROS-scavenging biomaterials for periodontitis | |
CN108348560A (zh) | 包含水飞蓟素和磺烃基醚环糊精的组合物及其使用方法 | |
WO2007075016A1 (en) | Collagenase inhibitor containing poly-gamma-glutamic acid-vitamin c complex and use thereof | |
CN1424900A (zh) | 局部皮肤用组合物 | |
Yu et al. | Chemically‐modified tetracycline normalizes collagen metabolism in diabetic rats: a dose‐response study | |
EP0871438B1 (en) | Use of alpha-hydroxy acids in the manufacture of a medicament for the treatment of inflammation | |
CN116531377B (zh) | 一种pH响应模拟缺氧效应纳米微球的制备方法及应用 | |
CN105708731B (zh) | 一种具有美白功效的生物微胶囊及其制备方法 | |
Wang et al. | Highly efficient photothermal branched Au–Ag nanoparticles containing procyanidins for synergistic antibacterial and anti-inflammatory immunotherapy | |
Colman et al. | Treatment of alcohol-related liver disease with (+)-cyanidanol-3: a randomised double-blind trial. | |
CN116531377A (zh) | 一种pH响应模拟缺氧效应纳米微球的制备方法及应用 | |
JP2003026572A (ja) | 含カルシウム組織強化剤並びにその用途 | |
Hu et al. | An injectable photopolymerizable chitosan hydrogel doped anti-inflammatory peptide for long-lasting periodontal pocket delivery and periodontitis therapy | |
EP2422777A1 (de) | Synergistische Wirkung von Modulatoren des NO-Stoffwechsels und der NADPH-Oxidase bei der Sensitivierung von Tumorzellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |